Diabetes

Better outcomes in T2DM with no delay in tx intensification

(HealthDay)—For patients with type 2 diabetes, not delaying intensification of oral antidiabetic drugs (OADs) is associated with greater reductions in hemoglobin A1c (HbA1c), and with reduced risks of cardiovascular events ...

Diabetes

Exenatide, pioglitazone effective for poorly controlled T2DM

(HealthDay)—For patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea, combination therapy with exenatide and pioglitazone is effective and safe, according to a study ...

Cardiology

Risk of ischemic, hemorrhagic stroke up with type 1 diabetes

(HealthDay)—The risks of ischemic and hemorrhagic stroke are increased with type 1 diabetes, with incrementally increasing risks with increasing hemoglobin A1c (HbA1c), according to a study published in the November issue ...

Diabetes

Impact of HbA1c, BMI changes on lipids varies as children age

(HealthDay)—As children age, the impact of changes in hemoglobin A1c (HbA1c) and body mass index (BMI) on low-density lipoprotein (LDL) and non-high-density lipoprotein (non-HDL) cholesterol levels increases, according ...

Diabetes

Gemigliptin, metformin combo beats monotherapy in T2DM

(HealthDay)—Gemigliptin combined with metformin is superior to monotherapy with either drug for patients with type 2 diabetes mellitus (T2DM), according to a study published online Sept. 13 in Diabetes, Obesity and Metabolism.

Diabetes

Quality improvement strategy ups achievement of T2DM goals

(HealthDay)—A multicomponent quality improvement (QI) strategy can improve achievement of diabetes care goals in a population of type 2 diabetes patients with poor cardiometabolic profiles, according to a study published ...

page 7 from 12